Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 5:12:966083.
doi: 10.3389/fonc.2022.966083. eCollection 2022.

The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance

Mohammad H Ghazimoradi  1 , Sadegh Babashah  1
Affiliations
Review

The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance

Mohammad H Ghazimoradi et al. Front Oncol. .

Abstract

Multidrug resistance is one of the major obstacles in the treatment of cancers. This undesirable feature increases the mortality rate of cancers, including breast cancer. Circular RNA (CircRNA)/microRNA (miRNA)/messenger RNA (mRNA) is one of the important axes with major roles in the promotion and resistance of breast cancer. This heterogeneous pathway includes mRNA of oncogenes and tumor suppressors, which are controlled by miRNAs and CircRNAs. Unfortunately, this network could be easily deregulated, resulting in drug resistance and tumor development. Therefore, understanding these dysregulations may thus help to identify effective therapeutic targets. On this basis, we try to review the latest findings in the field, which could help us to better comprehend this significant axis in breast cancer.

Keywords: breast cancer; circRNA; drug resistance; miRNA; oncogenes; tumor suppressors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Summary of significant drug resistance in the CircRNA/miRNA/mRNA axis in breast cancer.
Figure 2
Figure 2
CircRNA/miRNA/mRNA potential pathway for progression of breast cancer.
See this image and copyright information in PMC

References

    1. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature (2019) 575(7782):299–309. doi: 10.1038/s41586-019-1730-1 - DOI - PMC - PubMed
    1. Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis (2018) 35(4):309–18. doi: 10.1007/s10585-018-9903-0 - DOI - PubMed
    1. Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract (2020) 26(2):434–44. doi: 10.1177/1078155219877931 - DOI - PubMed
    1. Yao J, Deng K, Huang J, Zeng R, Zuo J. Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer. Front Pharmacol (2020) 1848. doi: 10.3389/fphar.2020.592912 - DOI - PMC - PubMed
    1. Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat (2021) 57:100770. doi: 10.1016/j.drup.2021.100770 - DOI - PubMed

LinkOut - more resources